XLO Stock Price, Xilio Therapeutics, Inc. Quote, Chart

Market Summary

USD1.14+0.06

Delayedas of 17 May 2024, 01:50 pm

5.56%

XLO Stock Price

View Fullscreen

XLO RSI Chart

XLO Valuation

Market Cap

39.9M

Price/Earnings (Trailing)

-0.56

Price/Free Cashflow

-0.73

XLO Price/Earnings (Trailing)

XLO Profitability

Return on Equity

-275.51%

Return on Assets

-85.93%

Free Cashflow Yield

-136.35%

XLO Fundamentals

XLO Earnings

Earnings (TTM)

-71.0M

Earnings Growth (Yr)

24.04%

Earnings Growth (Qtr)

2.7%

Breaking Down XLO Revenue

52 Week Range

1.063.25

(Low)(High)

Last 7 days

-13.5%

Last 30 days

-16.2%

Last 90 days

78.7%

Trailing 12 Months

-65.2%

How does XLO drawdown profile look like?

XLO Financial Health

Current Ratio

2.19

XLO Investor Care

Shares Dilution (1Y)

34.37%

Diluted EPS (TTM)

-2.57

Tracking the Latest Insider Buys and Sells of Xilio Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	gilead sciences, inc.	bought	368,790	0.76	485,250	-
Feb 08, 2024	atlas venture fund xi, l.p.	sold	-469	0.64	-733	-
Feb 08, 2024	atlas venture fund xi, l.p.	sold	-170	0.64	-267	-
Jan 12, 2024	atlas venture fund xi, l.p.	sold	-1,278	0.83	-1,540	-
Jan 12, 2024	atlas venture fund xi, l.p.	sold	-464	0.83	-560	-
Jan 11, 2024	atlas venture fund xi, l.p.	sold	-1,362	0.87	-1,566	-
Jan 11, 2024	atlas venture fund xi, l.p.	sold	-495	0.87	-569	-
Dec 10, 2021	bain capital life sciences investors, llc	bought	241,202	9.64809	25,000	-
Dec 09, 2021	bain capital life sciences investors, llc	bought	39,485	9.8442	4,011	-
Dec 08, 2021	bain capital life sciences investors, llc	bought	129,474	9.6206	13,458	-

Which funds bought or sold XLO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	8,315	16,945	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-28,280	-	-%
May 15, 2024	Royal Bank of Canada	added	13.89	1,000	1,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-54.28	-8,748	76,767	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	131	59,121	75,814	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	31,860	31,860	-%
May 15, 2024	Laurion Capital Management LP	sold off	-100	-64,266	-	-%
May 15, 2024	ArrowMark Colorado Holdings LLC	sold off	-100	-45,855	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-20.19	4,359	12,045	-%
May 15, 2024	Rock Springs Capital Management LP	unchanged	-	763,603	1,556,020	0.04%

Are Funds Buying or Selling XLO?

Are funds buying XLO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XLO

No. of Funds

Unveiling Xilio Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	rock springs capital management lp	8.71%	3,003,259	SC 13G/A
Apr 05, 2024	gilead sciences, inc.	19.9%	7,345,473	SC 13G
Feb 14, 2024	rock springs capital management lp	5.23%	1,440,759	SC 13G
Feb 06, 2024	octagon capital advisors lp	0%	0	SC 13G/A
Feb 05, 2024	octagon capital advisors lp	6.48%	1,785,000	SC 13G/A
Apr 10, 2023	mrl ventures fund llc	5.4%	1,483,414	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 25, 2023	octagon capital advisors lp	8.83%	2,425,000	SC 13G
Dec 29, 2022	flynn james e	0%	0	SC 13G/A
Nov 14, 2022	ra capital management, l.p.	0%	0	SC 13G/A

Recent SEC filings of Xilio Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 06, 2024	EFFECT	EFFECT
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
Apr 30, 2024	S-3	S-3
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Xilio Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Xilio Therapeutics, Inc. News

Latest updates

Xilio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	35.6%	83.00	61.00	78.00	92.00	112	139	157	178	196	218	121	36.00
Current Assets	43.8%	69.00	48.00	64.00	78.00	97.00	124	142	163	181	203	106	21.00
Cash Equivalents	-17.8%	37.00	45.00	60.00	75.00	93.00	120	139	159	177	200	100	21.00
Net PPE	-6.7%	6.00	6.00	6.00	7.00	7.00	7.00	8.00	7.00	7.00	8.00	7.00	7.00
Liabilities	135.9%	57.00	24.00	25.00	25.00	27.00	34.00	31.00	34.00	30.00	33.00	34.00	42.00
Current Liabilities	97.9%	32.00	16.00	17.00	16.00	16.00	21.00	17.00	18.00	12.00	13.00	13.00	22.00
Shareholder's Equity	-30.0%	26.00	37.00	52.00	67.00	85.00	106	126	144	166	185	-	-
Retained Earnings	-5.3%	-342	-325	-307	-291	-271	-249	-226	-206	-182	-160	-141	-85.09
Additional Paid-In Capital	1.7%	368	362	360	358	357	355	353	351	348	346	5.00	2.00
Shares Outstanding	24.9%	34.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	27.00	-	1.00
Float	-	-	-	-	68.00	-	-	-	70.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	21.8%	-10,502	-13,427	-13,369	-16,574	-25,250	-18,223	-19,909	-16,756	-20,835	-17,162	-20,719	-20,136	-22,734	-	-
Share Based Compensation	-5.0%	1,833	1,930	1,861	1,800	1,791	1,815	1,871	2,709	2,029	2,071	1,091	1,002	794	-	-
Cashflow From Investing	-	-	-	-	-316	-170	-509	-333	-771	-254	-378	-114	-438	-170	-	-
Cashflow From Financing	158.4%	954	-1,634	-2,236	-992	-1,688	-21.00	-22.00	-21.00	-5.00	115,826	301	-349	144,890	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XLO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 10,400	$ 16,131
General and administrative	6,139	7,395
Restructuring	948
Total operating expenses	17,487	23,526
Loss from operations	(17,487)	(23,526)
Other income, net
Other income, net	284	880
Total other income, net	284	880
Net loss	(17,203)	(22,646)
Comprehensive loss	$ (17,203)	$ (22,646)
Net loss per share, basic (in dollars per share)	$ (0.62)	$ (0.83)
Net loss per share, diluted (in dollars per share)	$ (0.62)	$ (0.83)
Weighted average common shares outstanding, basic (in shares)	27,912,584	27,433,252
Weighted average common shares outstanding, diluted (in shares)	27,912,584	27,433,252

XLO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 33,980	$ 44,704
License agreement receivable	30,000
Prepaid expenses and other current assets	5,205	3,423
Total current assets	69,185	48,127
Restricted cash	2,763	1,587
Property and equipment, net	5,542	5,942
Operating lease right-of-use asset	4,998	5,125
Other non-current assets	121	145
Total assets	82,609	60,926
Current liabilities
Accounts payable	746	1,050
Accrued expenses	8,002	10,497
Deferred revenue	21,725
Operating lease liability, current portion	1,081	1,047
Note payable, current portion		3,315
Other current liabilities	28	48
Total current liabilities	31,582	15,957
Deferred revenue, net of current portion	17,399
Operating lease liability, net of current portion	7,863	8,142
Total liabilities	56,844	24,099
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 34,473,486 shares issued and 34,472,646 shares outstanding at March 31, 2024; 27,613,263 shares issued and 27,607,646 shares outstanding at December 31, 2023	3	3
Additional paid-in capital	368,477	362,336
Accumulated deficit	(342,715)	(325,512)
Total stockholders' equity	25,765	36,827
Total liabilities and stockholders' equity	$ 82,609	$ 60,926

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
WEBSITE	https://xiliotx.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Xilio Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Xilio Therapeutics, Inc.? What does XLO stand for in stocks?

XLO is the stock ticker symbol of Xilio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xilio Therapeutics, Inc. (XLO)?

As of Thu May 16 2024, market cap of Xilio Therapeutics, Inc. is 39.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XLO stock?

You can check XLO's fair value in chart for subscribers.

What is the fair value of XLO stock?

You can check XLO's fair value in chart for subscribers. The fair value of Xilio Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xilio Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XLO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xilio Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether XLO is over valued or under valued. Whether Xilio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Xilio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XLO.